[October 20, 2016]

Global Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Pipeline Report 2016 - Research and Markets

Research and Markets has announced the addition of the "Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2016" report to their offering.

The report 'Free Fatty Acid Receptor 1 - Pipeline Review, H2 2016' outlays comprehensive information on the Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type that are being developed by Companies and Universities.

'Free Fatty Acid Receptor 1 - Pipeline Review, H2 2016': Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) pipeline Target (News - Alert) constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by Companies and remaining by Universities/Institutes.

Furthermore, the publisher says, Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Free fatty acid receptor 1 (FFA1), also known as GPR40, is a class A G-protein coupled receptor that is encoded by the FFAR1 gene. It is strongly expressed in the pancreatic islet cells and toa lesser extent in the brain. This membrane protein binds free fatty acids, acting as a nutrient sensor for regulating energy homeostasis.

It also reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Key Topics Covered:

1. Introduction
2. Free Fatty Acid Receptor 1 Overview
3. Therapeutics Development
4. Pipeline Products for Free Fatty Acid Receptor 1 - Overview
5. Pipeline Products for Free Fatty Acid Receptor 1 - Comparative Analysis
6. Free Fatty Acid Receptor 1 - Therapeutics under Development by Companies
7. Free Fatty Acid Receptor 1 - Therapeutics under Investigation by Universities/Institutes
8. Free Fatty Acid Receptor 1 Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Free Fatty Acid Receptor 1 - Products under Development by Companies
13. Free Fatty Acid Receptor 1 - Products under Investigation by Universities/Institutes
14. Free Fatty Acid Receptor 1 - Companies Involved in Therapeutics Development

• Advinus Therapeutics Ltd
• Amgen Inc.
• Astellas Pharma Inc.
• Caldan Therapeutics Limited
• Connexios Life Sciences Pvt. Ltd.
• Daiichi Sankyo Company, Limited
• Hyundai Pharmaceutical Co., Ltd.
• Japan Tobacco Inc.
• Jiangsu Hengrui Medicine Co., Ltd.
• Merck & Co., Inc.

For more information about this report visit http://www.researchandmarkets.com/research/wgsh3s/free_fatty_acid

View source version on businesswire.com: http://www.businesswire.com/news/home/20161020006390/en/

[ Back To TMCnet.com's Homepage ]